 DURHAM, N.C., Nov. 03, 2022 GLOBE NEWSWIRE -- Humacyte, Inc. Nasdaq: HUMA, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue, complex tissue systems, and organs at commercial scale, will release its financial results for the third quarter ended September 30, 2022, on Thursday, November 10, 2022. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. 